Pacira's long-acting pain drug advancing

En route to a potential FDA approval next month, Pacira Pharmaceuticals ($PCRX) reports data from previous trials of its lead drug Exparel for postsurgical pain. In patients who had surgery to enlarge their breasts and took the drug, there were no signs of ill effects in healing or breast appearance 13 months and two years after their surgeries. The data were presented on Sept. 24 at the annual American Society of Plastic Surgeons meeting in Denver. The FDA is expected to complete its review of the drug for postsurgical pain and decide whether to give it a market green light by Oct. 28. Exparel consists of the approved drug bupivacaine and is encased in liposome particles that enable the active ingredient to be released gradually. Release

Suggested Articles

Chiasma's new acromegaly pill Mycapssa, aiming to convert patients from injectables, turned out positive 48-week data from an extension study.

Medicated chewing gum is a prime drug delivery target, but it's tough to test. An experimental set of robot jaws could ease that burden.

J&J has new data that should convince regulators to clear its subcutaneous Darzalex in another indication—widening its edge over a Sanofi rival.